Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network



A critical gap in the adoption of genomic medicine into medical practice is the need for the rigorous evaluation of the utility of genomic medicine interventions.


The Implementing Genomics in Practice Pragmatic Trials Network (IGNITE PTN) was formed in 2018 to measure the clinical utility and cost-effectiveness of genomic medicine interventions, to assess approaches for real-world application of genomic medicine in diverse clinical settings, and to produce generalizable knowledge on clinical trials using genomic interventions. Five clinical sites and a coordinating center evaluated trial proposals and developed working groups to enable their implementation.


Two pragmatic clinical trials (PCTs) have been initiated, one evaluating genetic risk APOL1 variants in African Americans in the management of their hypertension, and the other to evaluate the use of pharmacogenetic testing for medications to manage acute and chronic pain as well as depression.


IGNITE PTN is a network that carries out PCTs in genomic medicine; it is focused on diversity and inclusion of underrepresented minority trial participants; it uses electronic health records and clinical decision support to deliver the interventions. IGNITE PTN will develop the evidence to support (or oppose) the adoption of genomic medicine interventions by patients, providers, and payers.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Structure of the IGNITE PTN.
Fig. 2: Organization of the Coordinating Center (CC).

Data availability

While this paper does not contain any primary research data, the IGNITE PTN will provide materials the Network has developed upon request. The PTN is particularly interested in supporting those interested in carrying out PCTs with genomic interventions. A goal of the PTN is to always make protocols, consents, clinical decision support rules, and code (where appropriate) available publicly.


  1. 1.

    National Human Genome Research Institute. Electronic Medical Records and Genomics (eMERGE) Network. (2020).

  2. 2.

    National Human Genome Research Institute. Clinical Sequencing Evidence-Generating Research (CSER). (2020).

  3. 3.

    National Human Genome Research Institute. The Clinical Genomic (ClinGen) Resource. (2020).

  4. 4.

    National Human Genome Research Institute. Implementing Genomics in Practice (IGNITE). (2020).

  5. 5.

    Weitzel, K. W. et al. The IGNITE network: a model for genomic medicine implementation and research. BMC Med. Genomics. 9, 1 (2016).

    Article  Google Scholar 

  6. 6.

    National Academies of Sciences, Engineering, and Medicine. An Evidence Framework for Genetic Testing. (National Academies Press, Washington, DC, 2017).

  7. 7.

    Harris, P. A. et al. Research electronic data capture (REDCap). A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 42, 377–381 (2009).

    Article  Google Scholar 

  8. 8.

    Harris, P. A. et al. The REDCap consortium: building an international community of software partners. J. Biomed. Inform. 95, 103208 (2019).

  9. 9.

    Groopman, E. E. et al. Diagnostic utility of exome sequencing for kidney disease. N. Engl. J. Med. 380, 142–151 (2019).

    CAS  Article  Google Scholar 

  10. 10.

    Carey, R. M. & Whelton, P. K., 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline. Ann. Intern. Med. 168, 351–358 (2018).

    Article  Google Scholar 

  11. 11.

    Cifu, A. S. & Davis, A. M. Prevention, detection, evaluation, and management of high blood pressure in adults. JAMA. 318, 2132–2134 (2017).

    Article  Google Scholar 

  12. 12.

    James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears in JAMA. 2014 May 7;311(17):1809]. JAMA. 311, 507–520 (2014).

    CAS  Article  Google Scholar 

  13. 13.

    Whelton, P. K. & Carey, R. M. The 2017 clinical practice guideline for high blood pressure. JAMA. 318, 2073–2074 (2017).

    Article  Google Scholar 

  14. 14.

    Qaseem, A. et al. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians [published correction appears in Ann. Intern. Med. 2018 Apr 3;168(7):530-532]. Ann. Intern. Med. 166, 430–437 (2017).

    Article  Google Scholar 

  15. 15.

    Duarte, J. D. et al. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J. 13, 257–263 (2013).

    CAS  Article  Google Scholar 

  16. 16.

    Collins, K. S. et al. Genotype-guided hydralazine therapy. Am. J. Nephrol. 51, 764–776 (2020).

    CAS  Article  Google Scholar 

  17. 17.

    Cavallari, L. H. et al. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet. Med. 21, 2255–2263 (2019).

    Article  Google Scholar 

  18. 18.

    US Food and Drug Administration. Jeffrey Shuren, M. D., J.D., director of the FDA’s Center for Devices and Radiological Health and Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research on agency’s warning to consumers about genetic tests that claim to predict patients’ responses to specific medications. (2018).

  19. 19.

    Fortier, I. et al. Is rigorous retrospective harmonization possible? Application of the DataSHaPER approach across 53 large studies. Int. J. Epidemiol. 40, 1314–1328 (2011).

    Article  Google Scholar 

  20. 20.

    Reid, M. C., Eccleston, C. & Pillemer, K. Management of chronic pain in older adults. BMJ. 350, h532 (2015).

  21. 21.

    Lesko, C. R. et al. Collaborative, pooled and harmonized study designs for epidemiologic research: challenges and opportunities. Int. J. Epidemiol. 47, 654–668 (2018).

    Article  Google Scholar 

  22. 22.

    Benet, M. et al. Integrating clinical and epidemiologic data on allergic diseases across birth cohorts: a harmonization study in the Mechanisms of the Development of Allergy Project. Am. J. Epidemiol. 188, 408–417 (2019).

    Article  Google Scholar 

Download references


This work was supported by grants from the National Institutes of Health (U01 HG007269, U01 HG010232, U01 HG010248, U01 HG010231, U01 HG0010245, U01 HG010225) and by the NIH IGNITE Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information





Conceptualization: all authors. Writing—original draft: all authors. Writing—review and editing: all authors. Funding acquisition: G.S.G., L.H.C., H.C., R.M.C.-D., P.R.D., M.T.E., B.S.F., C.R.H., J.J., L.A.O., J.P., T.C.S. Project administration: J.K., N.K., E.B.M., W.P., V.M.P., T.K.R.-B., M.A.R., N.S., K.-A.S.-B., S.L.V.D., D.V., K.W., A.G.W., S.V.

Corresponding author

Correspondence to Geoffrey S. Ginsburg.

Ethics declarations

Competing interests

L.H.C. has been funded by the NIH and FDA. She has received compensation as a consultant for LexiComp Inc. V.M.P. has has received compensation as an advisory board member of Avalon Healthcare Solutions. G.S.G. has been funded by NIH, the Department of Defense, and Abbott, Inc., and reports consulting for Konica-Minolta, Pappas Ventures, Fabric Genomics, and Peer Medical; he is a founder of Predigen Inc. T.C.S. has been funded by the NIH. He has received compensation as a consultant to Indiana University. He has received reimbursement for travel to a meeting by Tabula Rasa Healthcare. D.V. has been funded by NIH, AHA, AstraZeneca, and Department of Veterans Affairs. He has received compensation as a consultant from United Health Care. A.G.W. has been funded by the Merck & Co., FDA, NIH, the Bill and Melinda Gates Foundation and the State of Florida. The other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ginsburg, G.S., Cavallari, L.H., Chakraborty, H. et al. Establishing the value of genomics in medicine: the IGNITE Pragmatic Trials Network. Genet Med (2021).

Download citation


Quick links